Vaccinex enrolls 36 patients in KEYNOTE-B84 HNSCC study; interim analysis due mid-2023

VACCINEX, INC.

Phase 1b/2 trial evaluating pepinemab + KEYTRUDA in recurrent/metastatic HNSCC.
Enrollment of 36 subjects triggers pre-planned interim analysis; results expected mid-2023.
Primary endpoints: safety (TEAEs) and objective response rate (ORR).
Company notes improved durable responses in PD-L1 low (CPS<20) patient subset.
Full study plans to enroll ~62 patients; pepinemab global rights held by Vaccinex.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.